Business Description
Plus Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, dedicated to the development, manufacturing, and market introduction of therapeutic solutions for cancer patients and individuals with other serious illnesses. A cornerstone of their pipeline is Rhenium-186 NanoLiposome (R-186 NL), a patented radiotherapy specifically engineered to address difficult central nervous system (CNS) cancers, such as recurrent glioblastoma, leptomeningeal metastases, and various brain cancers affecting children. The company has also secured a licensing agreement with NanoTx, Corp. to advance and commercialize NanoTx's treatment for glioblastoma. Founded in 1996 and headquartered in Austin, Texas, the firm adopted its current name, Plus Therapeutics, Inc., in July 2019, having previously operated as Cytori Therapeutics, Inc.
Business History
Price Overview
Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): -7.19
Total Equity: $4.00M
Shares: 3,112,184
Total Debt: $821,000
Cash: $8.76M
EBITDA: -$18.33M
Total Debt: $821,000
Cash: $8.76M
Revenue: $5.21M
Shares: 3,112,184
Revenue: $5.21M
Revenue: $5.21M
Revenue: $5.21M
Total Equity: $4.00M
Tax Rate: 0.0%
Equity: $4.00M
Total Debt: $821,000
Cash: $8.76M
Current Liabilities: $12.31M
Long-Term Debt: $15,000
Total Debt: $821,000
Total Equity: $4.00M
Shares: 3,112,184
Shares: 3,112,184
CapEx: -$67,000
Shares: 3,112,184
Stock Price: $3.87
Net Income: -$22.39M
Industry Benchmarks
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
Income Statement (Annual)
Last updated: Jul 2, 2026 3:30pm (just now)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $224,000 | $4.9M | $5.8M | $5.2M |
| Cost of Revenue | $66,000 | $712,000 | $9.7M | $852,000 | $445,000 |
| Gross Profit | $-66,000 | $-488,000 | -$4.8M | $5.0M | $4.8M |
| Operating Expenses | $12.4M | $19.2M | $8.5M | $19.7M | $20.1M |
| Operating Income | -$12.5M | -$19.7M | -$13.3M | -$14.7M | -$15.3M |
| Net Income | -$13.4M | -$20.3M | -$13.3M | -$13.0M | -$22.4M |
| EBITDA | -$12.0M | -$18.9M | -$12.3M | -$8.4M | -$18.3M |
| EPS | $-444,500.00 | $-288,750.00 | $-106,000.00 | $-48.75 | $-7.19 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jul 2, 2026 3:30pm (just now)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $18.4M | $18.1M | $8.6M | $76,000 | $8.8M |
| Total Current Assets | $19.7M | $21.8M | $9.8M | $5.3M | $15.2M |
| Total Assets | $22.0M | $23.9M | $11.4M | $6.6M | $16.3M |
| Current Liabilities | $5.9M | $11.9M | $10.7M | $15.6M | $12.3M |
| Long-Term Debt | $5.0M | $3.8M | $0 | $0 | $15,000 |
| Total Liabilities | $11.1M | $17.4M | $12.7M | $15.6M | $12.3M |
| Total Equity | $10.8M | $6.4M | -$1.3M | -$8.9M | $4.0M |
| Retained Earnings | -$446.9M | -$467.2M | -$480.5M | -$493.5M | -$515.9M |
Cash Flow (Annual)
Last updated: Jul 2, 2026 3:30pm (just now)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$10.3M | -$13.0M | -$12.9M | -$10.6M | -$20.8M |
| Capital Expenditure | $-144,000 | $-759,000 | $-160,000 | $-146,000 | $-67,000 |
| Free Cash Flow | -$10.4M | -$13.7M | -$13.0M | -$10.7M | -$20.8M |
| Acquisitions (net) | $0 | $0 | $0 | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $-126,000 | $-374,000 | $0 |
| Net Change in Cash | $10.1M | $-280,000 | -$9.6M | -$8.5M | $8.7M |
Analyst Estimates (Annual)
Last updated: Jul 2, 2026 3:30pm (just now)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$20.2M $15.5M – $24.9M
|
$45.6M $45.4M – $45.7M
|
$121.3M $78.7M – $168.6M
|
$173.3M $112.4M – $240.8M
|
| EBITDA |
-$12.1M -$14.9M – -$9.3M
|
-$27.4M -$27.4M – -$27.3M
|
-$72.8M -$101.2M – -$47.2M
|
-$104.0M -$144.5M – -$67.4M
|
| Net Income |
-$7.3M -$7.8M – -$6.9M
|
-$1.1M -$1.9M – $-167,105
|
$5.2M $2.8M – $7.8M
|
$9.2M $5.0M – $13.9M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jul 2, 2026 3:30pm (just now)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | — | +2,093.3% | +18.5% | -10.5% |
| Gross Profit Growth | -639.4% | -878.9% | +204.1% | -4.1% |
| Operating Income Growth | -57.8% | +32.4% | -10.3% | -4.1% |
| Net Income Growth | -51.3% | +34.3% | +2.5% | -72.5% |
| EBITDA Growth | -56.5% | +34.8% | +31.7% | -118.2% |
Insider Trading (Recent)
All SEC Form 4 codes
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-07-01 | ANDREWS RONALD ASBURY | M-Exempt | 922.00 | $0.00 | $0 |
| 2026-07-01 | Guse Kyle | M-Exempt | 922.00 | $0.00 | $0 |
| 2026-07-01 | ANDREWS RONALD ASBURY | M-Exempt | 922.00 | $0.00 | $0 |
| 2026-07-01 | Guse Kyle | M-Exempt | 922.00 | $0.00 | $0 |
| 2026-07-01 | van Es-Johansson An | M-Exempt | 922.00 | $0.00 | $0 |
| 2026-07-01 | van Es-Johansson An | M-Exempt | 922.00 | $0.00 | $0 |
| 2026-07-01 | HEDRICK MARC H | M-Exempt | 6,387.00 | $0.00 | $0 |
| 2026-07-01 | HEDRICK MARC H | M-Exempt | 8,066.00 | $0.00 | $0 |
| 2026-07-01 | HEDRICK MARC H | M-Exempt | 1,986.00 | $0.00 | $0 |
| 2026-07-01 | HEDRICK MARC H | M-Exempt | 1,986.00 | $0.00 | $0 |
| 2026-07-01 | HEDRICK MARC H | M-Exempt | 8,066.00 | $0.00 | $0 |
| 2026-07-01 | HEDRICK MARC H | M-Exempt | 6,387.00 | $0.00 | $0 |
| 2026-07-01 | Clowes Howard | M-Exempt | 922.00 | $0.00 | $0 |
| 2026-07-01 | Clowes Howard | M-Exempt | 922.00 | $0.00 | $0 |
| 2026-07-01 | Hawkins Richard J | M-Exempt | 922.00 | $0.00 | $0 |
| 2026-07-01 | Hawkins Richard J | M-Exempt | 922.00 | $0.00 | $0 |
| 2026-07-01 | Sims Andrew John Hugh MacIntyre | M-Exempt | 1,533.00 | $0.00 | $0 |
| 2026-07-01 | Sims Andrew John Hugh MacIntyre | M-Exempt | 1,165.00 | $0.00 | $0 |
| 2026-07-01 | Sims Andrew John Hugh MacIntyre | M-Exempt | 287.00 | $0.00 | $0 |
| 2026-07-01 | Sims Andrew John Hugh MacIntyre | M-Exempt | 287.00 | $0.00 | $0 |
Narrative Economics
market-narrative step).